Segall Bryant & Hamill LLC Trims Stock Holdings in Pediatrix Medical Group, Inc. (NYSE:MD)

Segall Bryant & Hamill LLC reduced its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 5.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,244,950 shares of the company's stock after selling 74,289 shares during the period. Segall Bryant & Hamill LLC owned approximately 1.45% of Pediatrix Medical Group worth $14,429,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in MD. nVerses Capital LLC acquired a new stake in Pediatrix Medical Group in the 2nd quarter worth approximately $31,000. Innealta Capital LLC acquired a new position in shares of Pediatrix Medical Group in the 2nd quarter valued at $33,000. Quest Partners LLC lifted its position in Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company's stock worth $35,000 after acquiring an additional 622 shares during the period. Nisa Investment Advisors LLC grew its stake in Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock valued at $36,000 after purchasing an additional 1,524 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Pediatrix Medical Group in the second quarter worth about $72,000. Institutional investors and hedge funds own 97.71% of the company's stock.

Pediatrix Medical Group Trading Down 0.8 %

NYSE MD opened at $14.49 on Thursday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The stock's 50 day simple moving average is $12.77 and its 200-day simple moving average is $9.96. Pediatrix Medical Group, Inc. has a 1-year low of $6.62 and a 1-year high of $16.41.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same quarter last year, the firm posted $0.29 EPS. The firm's revenue for the quarter was up .9% on a year-over-year basis. Research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. UBS Group upped their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Jefferies Financial Group upped their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Mizuho raised their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a "neutral" rating in a report on Tuesday. Truist Financial increased their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a "hold" rating in a research report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a report on Monday, November 4th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $16.10.

Insider Transactions at Pediatrix Medical Group

In other news, Director Laura A. Linynsky sold 7,000 shares of the business's stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares of the company's stock, valued at approximately $343,783.80. The trade was a 18.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the business's stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now owns 138,683 shares in the company, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,808 shares of company stock valued at $751,277. Corporate insiders own 2.00% of the company's stock.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.